Predictors of grade 3-5 vesicoureteral reflux in infants ≤ 2 months of age with pyelonephritis.


Journal

Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728

Informations de publication

Date de publication:
05 2019
Historique:
received: 04 07 2018
accepted: 03 12 2018
revised: 03 12 2018
pubmed: 28 12 2018
medline: 6 5 2020
entrez: 28 12 2018
Statut: ppublish

Résumé

This study aimed to assess predictors for grade 3-5 vesicoureteral reflux (VUR) in infants ≤ 2 months of age admitted for first urinary tract infection (UTI). Retrospective cohort study of 195 infants ≤ 2 months admitted to a pediatric ward for first UTI between 2006 and 2017. Clinical, laboratory, and imaging data were collected from electronic medical charts. We examined associations between grade 3-5 VUR and different patient characteristics. Twenty infants (10%) were diagnosed with grade 3-5 VUR; all had fever. Infants with grade 3-5 VUR had higher blood neutrophil percentage (BNP) (65% vs. 46%, P < 0.001), higher neutrophil-to-lymphocyte ratio (NLR) (2.6 vs. 1.3, P < 0.001), more renal ultrasound abnormalities (prenatal 26% vs. 5%, P = 0.007; postnatal 84% vs. 55%, P = 0.015), and Pseudomonas UTI (15% vs. 1%, respectively, P < 0.001). NLR > 1.65 showed sensitivity 100% and specificity 61% for detecting grade 3-5 VUR. BNP > 53% showed sensitivity 100% and specificity 60% for detecting grade 3-5 VUR. BNP was the best single marker for grade 3-5 VUR with area under the curve (AUC) of 0.82 (95% CI 0.75-0.89). In a multivariate model, AUC for combination of BNP and hydronephrosis was 0.86 (95% CI 0.79-0.93, P = 0.007). Infants ≤ 2 months of age admitted for a first UTI are at risk for grade 3-5 VUR and thus should undergo a voiding cystourethrography (VCUG) if their renal ultrasound is abnormal or if they have Pseudomonas UTI. Avoiding VCUG can be considered in afebrile infants and in infants with BNP < 53% or NLR < 1.65.

Sections du résumé

BACKGROUND
This study aimed to assess predictors for grade 3-5 vesicoureteral reflux (VUR) in infants ≤ 2 months of age admitted for first urinary tract infection (UTI).
METHODS
Retrospective cohort study of 195 infants ≤ 2 months admitted to a pediatric ward for first UTI between 2006 and 2017. Clinical, laboratory, and imaging data were collected from electronic medical charts. We examined associations between grade 3-5 VUR and different patient characteristics.
RESULTS
Twenty infants (10%) were diagnosed with grade 3-5 VUR; all had fever. Infants with grade 3-5 VUR had higher blood neutrophil percentage (BNP) (65% vs. 46%, P < 0.001), higher neutrophil-to-lymphocyte ratio (NLR) (2.6 vs. 1.3, P < 0.001), more renal ultrasound abnormalities (prenatal 26% vs. 5%, P = 0.007; postnatal 84% vs. 55%, P = 0.015), and Pseudomonas UTI (15% vs. 1%, respectively, P < 0.001). NLR > 1.65 showed sensitivity 100% and specificity 61% for detecting grade 3-5 VUR. BNP > 53% showed sensitivity 100% and specificity 60% for detecting grade 3-5 VUR. BNP was the best single marker for grade 3-5 VUR with area under the curve (AUC) of 0.82 (95% CI 0.75-0.89). In a multivariate model, AUC for combination of BNP and hydronephrosis was 0.86 (95% CI 0.79-0.93, P = 0.007).
CONCLUSIONS
Infants ≤ 2 months of age admitted for a first UTI are at risk for grade 3-5 VUR and thus should undergo a voiding cystourethrography (VCUG) if their renal ultrasound is abnormal or if they have Pseudomonas UTI. Avoiding VCUG can be considered in afebrile infants and in infants with BNP < 53% or NLR < 1.65.

Identifiants

pubmed: 30588547
doi: 10.1007/s00467-018-4167-0
pii: 10.1007/s00467-018-4167-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

907-915

Commentaires et corrections

Type : CommentIn

Références

Pediatr Nephrol. 2017 Oct;32(10):1907-1913
pubmed: 28681079
Pediatr Radiol. 1985;15(2):105-9
pubmed: 3975102
J Pediatr. 2011 Jan;158(1):91-4
pubmed: 20708748
AJR Am J Roentgenol. 2015 Oct;205(4):894-8
pubmed: 26397341
Acta Paediatr. 2000 Jul;89(7):806-10
pubmed: 10943962
N Engl J Med. 2014 Jun 19;370(25):2367-76
pubmed: 24795142
Pediatr Radiol. 1993;23(6):478-80
pubmed: 8255658
J Urol. 1992 Nov;148(5 Pt 2):1667-73
pubmed: 1433585
Clin Pediatr (Phila). 2004 Sep;43(7):619-25
pubmed: 15378148
Eur Urol. 2012 Sep;62(3):534-42
pubmed: 22698573
Pediatr Emerg Care. 2004 Feb;20(2):85-8
pubmed: 14758304
Pediatr Emerg Care. 2012 Feb;28(2):125-30
pubmed: 22270498
Arch Dis Child. 1972 Apr;47(252):218-26
pubmed: 5023470
Iran J Pediatr. 2014 Aug;24(4):418-22
pubmed: 25755864
Urology. 2003 Jun;61(6):1238-42; discussion 1242-3
pubmed: 12809909
Korean J Pediatr. 2016 Mar;59(3):139-44
pubmed: 27186221
J Urol. 2012 Jan;187(1):265-71
pubmed: 22100009
J Pediatr. 2009 Jun;154(6):797-802
pubmed: 19230904
Pediatr Nephrol. 2006 Aug;21(8):1131-7
pubmed: 16810514
Pediatrics. 2011 Sep;128(3):595-610
pubmed: 21873693
Hosp Pediatr. 2016 Nov;6(11):647-652
pubmed: 27707778
BMJ. 2007 Aug 25;335(7616):395-7
pubmed: 17717369

Auteurs

Hilla Bahat (H)

Department of Pediatrics, Assaf Harofeh Medical Center, 70300, Zerifin, Israel. hilla.bahat@gmail.com.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. hilla.bahat@gmail.com.

Mai Ben-Ari (M)

Department of Pediatrics, Assaf Harofeh Medical Center, 70300, Zerifin, Israel.

Tomer Ziv-Baran (T)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Amos Neheman (A)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Urology, Assaf Harofeh Medical Center, Zerifin, Israel.

Ilan Youngster (I)

Department of Pediatrics, Assaf Harofeh Medical Center, 70300, Zerifin, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Michael Goldman (M)

Department of Pediatrics, Assaf Harofeh Medical Center, 70300, Zerifin, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH